NUVB

Nuvation Bio Inc.

$5.81 -0.30 (-4.91%) At close · Jul 10

Market Cap

$2.02B

348,201,971

Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date	Headline
2026-07-06	Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering
2026-06-29	Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdom
2026-06-26	Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes
2026-06-25	Nuvation Bio Announces Proposed Convertible Senior Notes Offering
2026-05-27	Nuvation Bio to Present at the Jefferies Global Healthcare Conference
2026-05-27	Nuvation Bio to Present New Quality-of-Life Data for IBTROZI® (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting
2026-05-13	Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI® for ROS1-Positive Non-Small Cell Lung Cancer
2026-05-06	Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung Cancer
2026-05-05	Nuvation Bio to Participate in Upcoming Investor Conferences
2026-05-04	Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update
2026-04-27	Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI®) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers
2026-04-21	Nuvation Bio Announces IBTROZI® (Taletrectinib) Showed Highly Durable Responses in Longer-Term Follow-up Data from Pivotal Studies Presented at AACR 2026
2026-04-20	Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026
2026-04-01	Nuvation Bio Announces Acquisition of Japan Rights to Safusidenib from Daiichi Sankyo

Past events

Date	Event	Type
2026-06-03	Jefferies Global Healthcare Conference	Conference
2026-05-26	TD Cowen’s 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA	Event
2026-05-20	2026 RBC Capital Markets Global Healthcare Conference	Conference
2026-05-19	H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ	Conference
2026-05-13	Bank of America Securities 2026 Healthcare Conference	Conference
2026-05-04	Nuvation Bio First Quarter 2026 Financial Results & Business Update	Event
2026-03-11	The Citizens Life Sciences Conference	Conference
2026-03-04	TD Cowen 46th Annual Health Care Conference	Conference
2026-03-02	Nuvation Bio Fourth Quarter and Full Year 2025 Financial Results & Business Update	Event
2026-01-13	44th Annual J.P. Morgan Healthcare Conference	Conference
2025-12-03	Citi 2025 Global Healthcare Conference	Conference
2025-12-02	8th Annual Evercore Healthcare Conference	Conference
2025-11-19	Jefferies Global Healthcare Conference in London	Conference
2025-11-03	Nuvation Bio Third Quarter 2025 Financial Results and Business Update	Event
2025-09-09	H.C. Wainwright 27th Annual Global Investment Conference	Conference
2025-09-04	Cantor Global Healthcare Conference 2025	Conference
2025-08-07	Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update	Event
2025-06-12	Nuvation Bio FDA Approval Conference Call	Conference
2025-05-28	TD Cowen 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA	Event
2025-05-21	2025 RBC Capital Markets Global Healthcare Conference	Conference
2025-05-20	H.C. Wainwright 3rd Annual BioConnect Investor Conference	Conference
2025-05-08	The Citizens Life Sciences Conference	Conference
2025-05-07	Nuvation Bio Q1 2025 and Business Update Conference Call	Earnings call
2025-04-09	Jones Healthcare and Technology Innovation Conference	Conference
2025-03-03	TD Cowen 45th Annual Health Care Conference	Conference

Source: https://investors.nuvationbio.com/investors/default.aspx

Key facts CIK 1811063 CUSIP 67080N101 13F (30d) 6 filings 6 filers Visit website Investor relations